BOT

3.91%

33.3¢ botanix pharmaceuticals ltd

Hmmmmmm, maybe because of this?'Endpoints in this phase 2...

First 7 Last

Share
Profile

Follow
Woodz13

40 Posts.

1

06/07/20

11:17

Post #: 45664773
Share
Originally posted by T.E.P.: ↑

Botanix is developing BTX 1503 as a novel treatment for moderate to severe acne.

Phase 1:
Botanix successfully completed a Phase 1b study of BTX 1503 during 1Q CY2018
The study achieved all the BTX 1503 program goals, indicating that it has an excellent safety profile, is very effective at reducing the number of inflammatory and non-inflammatory acne lesions, and provided an improvement in patient rated satisfaction
BTX 1503’s (on average) ~47% reduction in inflammatory lesions was greater than any other FDA-approved topical acne product for which data is available after four weeks of treatment

Phase 2:
However, the phase 2 results showed the primary endpoint in reduction in inflammatory lesions did not achieve statistical significance (even when considering AUS v US).
But, the secondary endpoint of reduction in non-inflammatory end points was statistically significant
It is the inflammatory lesions that are important.
Non-inflammatory lesions are simply comedones or pimples that have not yet broken through the skin are are not yet inflamed.

Ultimately, my outsider objective view is that:
The phase 2 trial was not a success
The market evidently agrees with me given the share price collapse
Progression to phase 3 is not guaranteed.

I'm impressed with the caliber of management of this company, but I am not yet convinced by the BTX1503 product.

To the bulls, why are you confident that the trial will continue into phase 3? Why are you confident that the market is wrong and that you are right and that we will return to the highs of old? Has the market overlooked the results of the phase 2 trial?

Willing to be convinced to buy in for a speculative trade -- I can't consider this an "investment" on current data yet.

T.E.P.

Expand

Hmmmmmm, maybe because of this?

'Endpoints in this phase 2 study already mirror those required in phase 3 studies for approval'
Last edited by Woodz13: 06/07/20

BOT Price at posting: 4.2¢ Sentiment: Buy Disclosure: Held
12 Upvote

1 Great analysis

Reply

Top Stories

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

PL3

Patagonia looks to raise $2.15M for South American exploration and development

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

There are more pages in this discussion • 41 more messages in this thread...

First 7 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 33.3¢		Change 0.013(3.91%)		Mkt cap ! $606.3M

Open	High	Low	Value	Volume
32.0¢	34.0¢	32.0¢	$1.472M	4.443M

Buyers (Bids)

No.	Vol.	Price($)
19	148622	33.0¢

Sellers (Offers)

Price($)	Vol.	No.
33.5¢	358119	11

View Market Depth

No.	Vol.	Price($)
20	178622	0.330
11	647750	0.325
27	1344140	0.320
14	1001633	0.315
22	2007358	0.310

Price($)	Vol.	No.
0.335	370227	11
0.340	735177	9
0.345	377331	10
0.350	265310	8
0.355	133069	6

Last trade - 15.47pm 09/07/2024 (20 minute delay)

BOT (ASX) Chart

Hmmmmmm, maybe because of this?'Endpoints in this phase 2...

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Hmmmmmm, maybe because of this?&apos;Endpoints in this phase 2...

Top Stories

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Hmmmmmm, maybe because of this?'Endpoints in this phase 2...